Procter & Gamble Health · NSE: PGHL · BSE: 500126
Q2 FY21 results · Jul–Sep 2020
Procter & Gamble Health reported revenue from operations of ₹263.97 crore (up 17.2% from Q2 FY20) and net profit of ₹59.26 crore (up 65.7% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a standalone basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 263.97 | 225.17 | +17.2% | — | — |
| Other income | 6.72 | 6.72 | −0.1% | — | — |
| Total income | 270.69 | 231.89 | +16.7% | — | — |
| Profit before tax | 77.22 | 52.58 | +46.9% | — | — |
| Net profit for the period | 59.26 | 35.76 | +65.7% | — | — |
| EPS, basic (₹) | 35.70 | 21.54 | +65.7% | — | — |
| Net margin (%) | 22.4 | 15.9 | — |
Standalone
- Filed with BSE
- 12 Nov 2020, 08:24 IST
- Board meeting
- 11 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE